BR0017030B1 - derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos - Google Patents
derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmosInfo
- Publication number
- BR0017030B1 BR0017030B1 BRPI0017030-5B1A BR0017030A BR0017030B1 BR 0017030 B1 BR0017030 B1 BR 0017030B1 BR 0017030 A BR0017030 A BR 0017030A BR 0017030 B1 BR0017030 B1 BR 0017030B1
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- pharmaceutical composition
- thiazolylamide
- derivatives
- thiazolylamide derivatives
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19962532A DE19962532A1 (de) | 1999-12-23 | 1999-12-23 | Thiazolylamid-Derivate |
| DE10039265A DE10039265A1 (de) | 2000-08-11 | 2000-08-11 | Thiazolylamid-Derivate |
| PCT/EP2000/012564 WO2001047904A1 (de) | 1999-12-23 | 2000-12-12 | Thiazolylamid-derivate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0017030A BR0017030A (pt) | 2003-01-07 |
| BR0017030B1 true BR0017030B1 (pt) | 2013-10-01 |
| BR0017030B8 BR0017030B8 (pt) | 2021-05-25 |
Family
ID=26006669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0017030A BR0017030B8 (pt) | 1999-12-23 | 2000-12-12 | derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7105553B2 (pt) |
| EP (1) | EP1244641B1 (pt) |
| JP (1) | JP4726175B2 (pt) |
| KR (1) | KR100768361B1 (pt) |
| CN (1) | CN1235890C (pt) |
| AR (1) | AR029210A1 (pt) |
| AT (1) | ATE293104T1 (pt) |
| AU (1) | AU784286B2 (pt) |
| BR (1) | BR0017030B8 (pt) |
| CA (1) | CA2396720C (pt) |
| CO (1) | CO5261491A1 (pt) |
| DE (1) | DE50010060D1 (pt) |
| DK (1) | DK1244641T3 (pt) |
| DO (1) | DOP2000000109A (pt) |
| ES (1) | ES2240233T3 (pt) |
| IL (2) | IL149897A0 (pt) |
| MX (1) | MXPA02006243A (pt) |
| MY (1) | MY134880A (pt) |
| NZ (1) | NZ519701A (pt) |
| PE (1) | PE20010964A1 (pt) |
| PL (1) | PL208707B1 (pt) |
| PT (1) | PT1244641E (pt) |
| SV (1) | SV2002000249A (pt) |
| TW (1) | TWI256951B (pt) |
| UY (1) | UY26495A1 (pt) |
| WO (1) | WO2001047904A1 (pt) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2000259734A1 (en) * | 2000-06-15 | 2001-12-24 | Gerald Kleymann | Method for identifying compounds with anti-herpes activity |
| DE10129714A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Topische Anwendung von Thiazolylamiden |
| DE10131128A1 (de) * | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| AR036873A1 (es) | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
| ATE488248T1 (de) * | 2004-09-09 | 2010-12-15 | Novartis Vaccines & Diagnostic | Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen |
| DE102005014248A1 (de) * | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| EP2029138A1 (en) * | 2005-06-03 | 2009-03-04 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| US20070032488A1 (en) * | 2005-08-05 | 2007-02-08 | Genelabs Technologies, Inc. | 6-Membered aryl and heteroaryl derivatives for treating viruses |
| KR20080090381A (ko) * | 2005-08-29 | 2008-10-08 | 제라드 엠. 하우지 | 테라뮤틴 조절물질 |
| MX368352B (es) * | 2006-03-17 | 2019-09-30 | Univ Johns Hopkins | Derivados de n-hidroxilsulfonamida como nuevos donantes de nitroxilo fisiologicamente utiles. |
| JP2010510168A (ja) * | 2006-11-22 | 2010-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 官能化窒化ホウ素ナノチューブ |
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| EP2573086A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| AU2014217962A1 (en) | 2013-02-12 | 2015-09-17 | Aicuris Gmbh & Co. Kg | Helicase-primase inhibitors for use in a method of treating Alzheimer's Disease |
| BR112017000285A2 (pt) * | 2014-07-07 | 2017-10-31 | Prophylaxis LLC | métodos de tratamento da profilaxia viral e kits de profilaxia de pré-exposição |
| EA035401B1 (ru) * | 2016-04-06 | 2020-06-08 | Инновейтив Молекьюлз Гмбх | Производные аминотиазола, полученные в качестве противовирусных средств |
| UY37497A (es) | 2016-11-28 | 2018-06-29 | Aicuris Anti Infective Cures Gmbh | Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida |
| LT3544976T (lt) * | 2016-11-28 | 2021-08-10 | Aicuris Gmbh & Co. Kg | N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamido laisvos bazės hemihidratas, jo gamybos būdai ir panaudojimai |
| PL3544977T3 (pl) | 2016-11-28 | 2021-11-08 | Aicuris Gmbh & Co. Kg | Sól maleinianowa wolnej zasady n-[5-(aminosulfonylo)-4-metylo-1,3-tiazol-2-ilo]-n-metylo-2-[4-(2-pirydynylo)fe¬nylo]acetamidu, preparaty farmaceutyczne, sposoby wytwarzania oraz ich zastosowania do leczenia wirusa opryszczki |
| EP3566749A4 (en) * | 2017-01-09 | 2020-09-23 | Medshine Discovery Inc. | THIAZOLE DERIVATIVE AND USES OF IT |
| MX2020003369A (es) | 2017-10-05 | 2020-07-29 | Innovative Molecules Gmbh | Enantiomeros de tiazoles sustituidos como compuestos antivirales. |
| CN112384512B (zh) * | 2018-07-06 | 2022-03-29 | 辉诺生物医药科技（杭州）有限公司 | 噻唑类化合物的晶型及其应用 |
| CA3168721A1 (en) | 2020-03-26 | 2021-09-30 | Jessica Redmer | Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate |
| EP3925595A1 (en) | 2020-06-17 | 2021-12-22 | AiCuris GmbH & Co. KG | Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate |
| MX2023004955A (es) * | 2020-10-29 | 2023-05-17 | Innovative Molecules Gmbh | Compuestos de aminotiazol deuterados como compuestos antiviricos. |
| IL314188A (en) | 2022-01-17 | 2024-09-01 | Innovative Molecules Gmbh | Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof |
| JP2025527942A (ja) | 2022-08-29 | 2025-08-25 | アセンブリー・バイオサイエンシーズ・インコーポレイテッド | 新規な結晶形態 |
| EP4581031A1 (en) | 2022-08-29 | 2025-07-09 | Assembly Biosciences, Inc. | A novel crystalline form of pritelivir |
| WO2024047508A1 (en) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | Pharmaceutical compositions for herpes virus |
| EP4581029A1 (en) | 2022-08-29 | 2025-07-09 | Assembly Biosciences, Inc. | Cyclic urea thiazolyl compounds for treatment of hsv |
| WO2024224304A1 (en) | 2023-04-26 | 2024-10-31 | Assembly Biosciences, Inc. | Oral pharmaceutical compositions |
| WO2025046457A1 (en) | 2023-08-28 | 2025-03-06 | Assembly Biosciences, Inc. | A crystalline form of 2-(3-(2,,5'-difluoro-[1,1'-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2h)-yl)-4-methylthiazole-5-sulfonamide |
| WO2025046456A1 (en) | 2023-08-28 | 2025-03-06 | Assembly Biosciences, Inc. | A crystalline form of 2-(3-(2,,5'-difluoro-[1,1'-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2h)-yl)-4-methylthiazole-5-sulfonamide |
| WO2025111598A1 (en) | 2023-11-22 | 2025-05-30 | Assembly Biosciences, Inc. | Azetidine compounds for treatment of hsv |
| WO2025172927A1 (en) | 2024-02-16 | 2025-08-21 | Assembly Biosciences, Inc. | Pharmaceutical compositions for herpes virus |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7100497A (pt) | 1970-01-16 | 1971-07-20 | ||
| US3658830A (en) | 1970-01-16 | 1972-04-25 | Shell Oil Co | 5-(substituted mercapto sulfiny sulfonyl or sulfamoyl) |
| US3717651A (en) | 1970-04-20 | 1973-02-20 | Shell Oil Co | Thiazoles |
| US3847588A (en) | 1970-04-20 | 1974-11-12 | Shell Oil Co | Thiazoles herbicidal |
| PT871619E (pt) | 1995-12-29 | 2003-03-31 | Boehringer Ingelheim Pharma | Derivados de fenil-tiazol com propriedades anti-virus do herpesc |
| US5705344A (en) | 1996-03-14 | 1998-01-06 | Tularik, Inc. | High-throughput screening assay for inhibitors of nucleic acid helicases |
| GB2311069A (en) | 1996-03-14 | 1997-09-17 | Merck & Co Inc | Primase isolated from human cytomegalovirus (HCMV) |
| GB2311068A (en) | 1996-03-14 | 1997-09-17 | Merck & Co Inc | Helicase isolated from human cytomegalovirus (HCMV) |
| CA2223032A1 (en) | 1997-02-21 | 1998-08-21 | Smithkline Beecham Corporation | Use of hsv-1 ul-15 and vp5 in identifying anti-viral agents |
| DE19802437A1 (de) * | 1998-01-23 | 1999-07-29 | Bayer Ag | Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe |
| AU3289299A (en) | 1998-02-19 | 1999-09-06 | Tularik Inc. | Antiviral agents |
| ATE229945T1 (de) | 1998-03-19 | 2003-01-15 | Upjohn Co | Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole |
| WO2000053591A1 (de) | 1999-03-08 | 2000-09-14 | Bayer Aktiengesellschaft | Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel |
-
2000
- 2000-12-05 DO DO2000000109A patent/DOP2000000109A/es unknown
- 2000-12-12 WO PCT/EP2000/012564 patent/WO2001047904A1/de not_active Ceased
- 2000-12-12 CN CNB008189676A patent/CN1235890C/zh not_active Expired - Lifetime
- 2000-12-12 CA CA002396720A patent/CA2396720C/en not_active Expired - Lifetime
- 2000-12-12 AT AT00991169T patent/ATE293104T1/de active
- 2000-12-12 KR KR1020027008155A patent/KR100768361B1/ko not_active Expired - Lifetime
- 2000-12-12 ES ES00991169T patent/ES2240233T3/es not_active Expired - Lifetime
- 2000-12-12 DE DE50010060T patent/DE50010060D1/de not_active Expired - Lifetime
- 2000-12-12 MX MXPA02006243A patent/MXPA02006243A/es active IP Right Grant
- 2000-12-12 JP JP2001549375A patent/JP4726175B2/ja not_active Expired - Lifetime
- 2000-12-12 PL PL356484A patent/PL208707B1/pl unknown
- 2000-12-12 DK DK00991169T patent/DK1244641T3/da active
- 2000-12-12 IL IL14989700A patent/IL149897A0/xx active IP Right Grant
- 2000-12-12 AU AU31574/01A patent/AU784286B2/en not_active Expired
- 2000-12-12 US US10/168,197 patent/US7105553B2/en not_active Expired - Lifetime
- 2000-12-12 NZ NZ519701A patent/NZ519701A/en not_active IP Right Cessation
- 2000-12-12 EP EP00991169A patent/EP1244641B1/de not_active Expired - Lifetime
- 2000-12-12 BR BRPI0017030A patent/BR0017030B8/pt not_active IP Right Cessation
- 2000-12-12 PT PT00991169T patent/PT1244641E/pt unknown
- 2000-12-20 AR ARP000106789A patent/AR029210A1/es active IP Right Grant
- 2000-12-20 UY UY26495A patent/UY26495A1/es not_active Application Discontinuation
- 2000-12-21 MY MYPI20006089A patent/MY134880A/en unknown
- 2000-12-22 SV SV2000000249A patent/SV2002000249A/es active IP Right Grant
- 2000-12-22 TW TW089127599A patent/TWI256951B/zh not_active IP Right Cessation
- 2000-12-22 PE PE2000001387A patent/PE20010964A1/es not_active IP Right Cessation
- 2000-12-22 CO CO00097414A patent/CO5261491A1/es active IP Right Grant
-
2002
- 2002-05-28 IL IL149897A patent/IL149897A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0017030B1 (pt) | derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos | |
| BR0008840B1 (pt) | derivados de camptotecina, processos para a sua preparaÇço, composiÇço farmacÊutica que os compreende e uso dos mesmos. | |
| BR9910900B1 (pt) | compostos derivados de isotiazol, processo para sua preparação e composição farmacêutica dos mesmos | |
| BR9710739B1 (pt) | polissacarÍdeos sintÉticos, processo para sua preparaÇço, composiÇÕes farmacÊuticas que os contÊm e utilizaÇço dos mesmos. | |
| PT1192122E (pt) | Derivados de benzeno processo para a sua preparacao e composicoes farmaceuticas que os contem | |
| BR9706471B1 (pt) | derivados de propiofenona, processo para prepração dos mesmos, composição farmacêutica compreendendo os mesmos, bem com seu uso. | |
| BR9909995B1 (pt) | composto, processo para a preparação de um composto, formulação farmacêutica, e, uso de um composto. | |
| BR9501770A (pt) | Uso de um composto,composto,formulação farmacêutica e processo para preparar um composto | |
| BR9707251A (pt) | Compostos processo para a preparação dos mesmos e composições farmacêuticas | |
| EE200100431A (et) | 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine | |
| PT1339675E (pt) | Compostos bisarilo orto, meta-substituidos, processo para a sua preparacao, sua utilizacao como medicamentos e composicoes farmaceuticas que os contem | |
| EE04464B1 (et) | Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid | |
| BR9801606B1 (pt) | composto, processo para sua preparação, substáncia farmacêutica, uso do composto e processo para a produção de uma substáncia farmacêutica. | |
| BR9808422B1 (pt) | composto, composiÇço farmacÊutica, uso de um composto, e, processo para a preparaÇço de um composto. | |
| BR9711311B1 (pt) | derivado de 1,2,3,4-tetrahidroquinolina, composiÇço farmaceutica, uso de um derivado de 1,2,3,4-tetrahidroquinolina, e, processo para a preparaÇço de compostos. | |
| EE03825B1 (et) | 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid | |
| BR9506106A (pt) | Composto processo para sua preparação medicamento e composição farmacêutica | |
| BR1100524A (pt) | Compostos, processo para sua preparação; compostos intermediários para os mesmos, e composições farmacêuticas | |
| EE04346B1 (et) | Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon | |
| BR9701085A (pt) | Derivado de vitamina d cristalina processo para preparar o mesmo medicamento composição farmacéutica processo para preparar a mesma e uso do derivado | |
| PT1118610E (pt) | Novos derivados de benzeno-sulfonamida processo para a sua preparacao e as composicoes farmaceuticas que os contem | |
| BR9602025A (pt) | Composto composição farmacêutica uso e processo para a preparação de um composto | |
| BR9503876A (pt) | Quinoxalina-2,3-diona-oxa-ou tec-alifaticamente ligada em ponte processo para sua preparação compostos uso dos mesmos e composições farmacêuticas | |
| EE03996B1 (et) | Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine | |
| PT939083E (pt) | Complexos de ferro-succinilcaseina procedimento para sua preparacao e suas composicoes farmaceuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: AICURIS GMBH AND CO. KG (DE) Free format text: TRANSFERIDO DE: BAYER AKTIENGESELLSCHAFT |
|
| B25G | Requested change of headquarter approved |
Owner name: AICURIS GMBH AND CO. KG (DE) Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070107873/RJ DE 03/08/2007. |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] |
Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO. |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/10/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/12/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 12/12/2020 |